64 related articles for article (PubMed ID: 2697948)
1. [Relevance of fibrinogen/fibrin degradation products in the study of thrombosis].
Páramo JA; Gaffney PJ
Sangre (Barc); 1989 Dec; 34(6):497-501. PubMed ID: 2697948
[No Abstract] [Full Text] [Related]
2. [Thrombus formation with special reference to the substrates, fibrinogen and its related substances].
Matsuda M
Rinsho Ketsueki; 1984 Jul; 25(7):984-91. PubMed ID: 6502959
[No Abstract] [Full Text] [Related]
3. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis.
Smith EB
Clin Haematol; 1986 May; 15(2):355-70. PubMed ID: 3524931
[TBL] [Abstract][Full Text] [Related]
4. Proteolytic degradation products from fibrinogen and fibrin with special respect to non-covalently associated complexes. Influence of fibrin crosslinking. Lysability and other properties.
Feddersen C
Scand J Clin Lab Invest Suppl; 1983; 166():1-60. PubMed ID: 6226084
[No Abstract] [Full Text] [Related]
5. [Biological effect of fibrin/fibrinogen degradation products].
Li SQ
Sheng Li Ke Xue Jin Zhan; 1986 Apr; 17(2):169-72. PubMed ID: 3538403
[No Abstract] [Full Text] [Related]
6. Fibrinogen-fibrin degradation products.
Kwaan HC
Ann Clin Lab Sci; 1980; 10(3):234-7. PubMed ID: 7396389
[TBL] [Abstract][Full Text] [Related]
7. [Importance of fibrin-fibrinogen degradation products in the pathogenesis of a coagulopathy in leukemias].
Krasik IaD; Fedorova ZD; Elizarova AI; Rozanova LM; Bazhenov EL
Probl Gematol Pereliv Krovi; 1980 Mar; 25(3):13-8. PubMed ID: 6929066
[No Abstract] [Full Text] [Related]
8. [Fluctuation of plasma levels of fibrinogen degradation products, fibrin degradation products and total fibrin/fibrinogen degradation products in patients with DIC].
Isogai N; Kuroso K; Fujimaki M; Yorifuji H; Fukutake K
Rinsho Byori; 1993 Dec; 41(12):1349-52. PubMed ID: 8295346
[TBL] [Abstract][Full Text] [Related]
9. [Possibilities of using immunoenzyme test systems for determining levels of myoglobin, fibrinogen, fibrin-fibrinogen degradation products and fibronectin in the diagnosis of somatic diseases].
Ermolin GA; Shelepova TM; Dikov MM; Osmanov SK; Voloshchuk OM
Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1987; 10(1):33-7. PubMed ID: 3300700
[TBL] [Abstract][Full Text] [Related]
10. Fibrinogen degradation products do not affect the hypertensive action of dopamine.
Buczko W; Wiśniewski K
Acta Med Pol; 1986; 27(1-2):31-6. PubMed ID: 3565076
[No Abstract] [Full Text] [Related]
11. [Nonenzymatic fibrinolysis].
Dzhurdzhev A; Atanasov K
Vutr Boles; 1981; 20(3):18-22. PubMed ID: 6455858
[No Abstract] [Full Text] [Related]
12. Specific identification of urinary fibrinogen, fibrinogen degradation products, and cross-linked fibrin degradation products in renal diseases and after renal allotransplantation.
Scott WL; Francis CW; Knutson DW; Marder VJ
J Lab Clin Med; 1986 Jun; 107(6):534-43. PubMed ID: 3519810
[TBL] [Abstract][Full Text] [Related]
13. Are fibrin-related markers useful for the diagnosis of thrombosis?
Wada H; Sakuragawa N
Semin Thromb Hemost; 2008 Feb; 34(1):33-8. PubMed ID: 18393141
[TBL] [Abstract][Full Text] [Related]
14. Measurement of autoantibodies against fibrinogen and fibrin degradation products by enzyme-linked immunoassay.
Whitaker AN; McFarlane JR; Rowe EA; Lee K; Masci PP
Thromb Haemost; 1985 Feb; 53(1):80-5. PubMed ID: 3992524
[TBL] [Abstract][Full Text] [Related]
15. [Various aspects of the regulation and role of fibrinolysis in the organism].
Myśliwiec M
Rocz Akad Med Im Juliana Marchlewskiego Bialymst; 1982; 27():21-63. PubMed ID: 6820837
[No Abstract] [Full Text] [Related]
16. Use of fibrinogen and fibrin D-dimer in prediction of arterial thrombotic events.
Lowe GD; Rumley A
Thromb Haemost; 1999 Aug; 82(2):667-72. PubMed ID: 10605766
[No Abstract] [Full Text] [Related]
17. Lack of effects of fibrinogen degradation products on specific binding of [3H]spiroperidol and [3H]ADTN.
Buczko W; De Blasi A
Pol J Pharmacol Pharm; 1983; 35(1):45-7. PubMed ID: 6889186
[TBL] [Abstract][Full Text] [Related]
18. [Fibrin and fibrinogen degradation products in suspected deep venous thrombosis of the lower extremities].
Sørensen MD; Ott P; Gad I; Gyhrs S; Iversen D; Treufeldt P
Ugeskr Laeger; 1988 Jan; 150(1):20-2. PubMed ID: 3376204
[No Abstract] [Full Text] [Related]
19. [Physiopathology of consumption coagulopathies].
Cuocolo R; Ortolani O; Conti A
Minerva Anestesiol; 1980 Jul; 46(7):827-42. PubMed ID: 7017463
[No Abstract] [Full Text] [Related]
20. Biological properties of fibrinogen derivatives relevant to the function of cardiovascular system and immuno-inflammatory reaction.
Kopec M
New Istanbul Contrib Clin Sci; 1977 Sep; 12(1):43-9. PubMed ID: 565049
[No Abstract] [Full Text] [Related]
[Next] [New Search]
